181 related articles for article (PubMed ID: 12592324)
21. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
[TBL] [Abstract][Full Text] [Related]
22. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
[TBL] [Abstract][Full Text] [Related]
23. Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck.
Yokoyama N; Miller WT
J Biol Chem; 2003 Nov; 278(48):47713-23. PubMed ID: 14506255
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
[TBL] [Abstract][Full Text] [Related]
25. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Wang Y; Liu J; Wu Y; Luo W; Lin SH; Lin H; Hawk N; Sun T; Guo JQ; Estrov Z; Talpaz M; Champlin R; Arlinghaus RB
Cancer Res; 2001 Jan; 61(1):138-44. PubMed ID: 11196151
[TBL] [Abstract][Full Text] [Related]
26. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Arlinghaus RB
Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
[TBL] [Abstract][Full Text] [Related]
27. Molecular and structural characterization of the SH3 domain of AHI-1 in regulation of cellular resistance of BCR-ABL(+) chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Liu X; Chen M; Lobo P; An J; Grace Cheng SW; Moradian A; Morin GB; Van Petegem F; Jiang X
Proteomics; 2012 Jul; 12(13):2094-106. PubMed ID: 22623184
[TBL] [Abstract][Full Text] [Related]
28. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.
Meyn MA; Wilson MB; Abdi FA; Fahey N; Schiavone AP; Wu J; Hochrein JM; Engen JR; Smithgall TE
J Biol Chem; 2006 Oct; 281(41):30907-16. PubMed ID: 16912036
[TBL] [Abstract][Full Text] [Related]
29. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
[TBL] [Abstract][Full Text] [Related]
30. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
31. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
32. Intramolecular regulatory interactions in the Src family kinase Hck probed by mutagenesis of a conserved tryptophan residue.
LaFevre-Bernt M; Sicheri F; Pico A; Porter M; Kuriyan J; Miller WT
J Biol Chem; 1998 Nov; 273(48):32129-34. PubMed ID: 9822689
[TBL] [Abstract][Full Text] [Related]
33. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
Liu J; Wu Y; Arlinghaus RB
Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
[TBL] [Abstract][Full Text] [Related]
34. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
35. Affinity of Src family kinase SH3 domains for HIV Nef in vitro does not predict kinase activation by Nef in vivo.
Briggs SD; Lerner EC; Smithgall TE
Biochemistry; 2000 Jan; 39(3):489-95. PubMed ID: 10642173
[TBL] [Abstract][Full Text] [Related]
36. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
[TBL] [Abstract][Full Text] [Related]
37. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
[TBL] [Abstract][Full Text] [Related]
38. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R
Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338
[TBL] [Abstract][Full Text] [Related]
39. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
Muller AJ; Young JC; Pendergast AM; Pondel M; Landau NR; Littman DR; Witte ON
Mol Cell Biol; 1991 Apr; 11(4):1785-92. PubMed ID: 2005881
[TBL] [Abstract][Full Text] [Related]
40. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain.
Schreiner SJ; Schiavone AP; Smithgall TE
J Biol Chem; 2002 Nov; 277(47):45680-7. PubMed ID: 12244095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]